Once-daily indacaterol versus twice-daily salmeterol for COPD: A placebo-controlled comparison

European Respiratory Journal

Volumn 37, Issue 2, 2011, Pages 273-279

  Kornmann, O ^a   Dahl, R ^b   Centanni, S ^c   Dogra, A ^d   Owen, R ^e   Lassen, C ^e   Kramer, B ^d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF MILAN   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Clinical trial; Indacaterol; Salmeterol

Indexed keywords

INDACATEROL; PLACEBO; SALMETEROL;

ADULT; ARTICLE; BACKACHE; BACTERIAL INFECTION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; SINGLE DRUG DOSE; TRANSITIONAL DYSPNEA INDEX; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; HEALTH STATUS; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; QUINOLONES; RESPIRATORY FUNCTION TESTS; SMOKING;

EID: 79953026850     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00045810     Document Type: Article

References (27)

1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750. (Pubitemid 47321907)
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773. (Pubitemid 47321908)
3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. www.goldcopd.com/ GuidelineItem.asp?intId=1386 Date last accessed: January 17, 2010. Date last updated: 2009.
4. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-162.
5. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 2010; 65: 473-479.
6. Global initiative for chronic obstructive lung disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. www.goldcopd.com Date last accessed: January 17, 2010. Date last updated: 2005.
7. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
8. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
9. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
10. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21: 267-272. (Pubitemid 36204541)
11. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-874.
12. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slowrelease theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069. (Pubitemid 34280423)
13. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965. (Pubitemid 29193661)
14. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
15. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55. (Pubitemid 34754142)
16. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 mg)/salmeterol (50 mg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843. (Pubitemid 37123298)
17. Hodder R, Kesten S, Menjoge S, et al. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2007; 2: 157-167. (Pubitemid 47202216)
18. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-2048.
19. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
20. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670. (Pubitemid 32744919)
21. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456. (Pubitemid 36173708)
22. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012. (Pubitemid 38269277)
23. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257. (Pubitemid 44883863)
24. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
25. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-2646. (Pubitemid 41507622)
26. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033-1044.
27. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20: 740-749.